Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04388774

Low-Dose Ketamine in Children With ADNP Syndrome

A Phase 2A Open-Label Study Evaluating the Safety and Efficacy of Low-Dose Ketamine in Children With ADNP Syndrome

Sponsor: Alexander Kolevzon

Interventions Ketamine

Updated 7 times since 2020 Last updated: Jul 5, 2023 Started: Aug 19, 2020 Primary completion: Jun 8, 2021 Completion: Jun 8, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04388774, this PHASE1/PHASE2 trial focuses on ADNP Syndrome and remains completed. Sponsored by Alexander Kolevzon, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Sep 2021 — Aug 2023 [monthly]

Completed PHASE1_PHASE2

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Jun 2020 — Oct 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexander Kolevzon

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States